# US 2021/0061880 A1 · Single-chain cd27-receptor agonist proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0061880 A1
- Document ID: US20210061880A1
- Status: Published application
- Kind: A1
- Application number: 16/950,755
- Filed: 2020-11-17
- Published: 2021-03-04
- Earliest claimed: 2015-10-23
- Assignees: Apogenix AG
- Applicants: Apogenix AG
- Inventors: Christian GIEFFERS; Oliver HILL; Meinolf THIEMANN; Tim SCHNYDER
- Web page: https://patentgrep.com/patent/US20210061880A1

## CPC

- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2818: {against CD28 or CD152}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/22: containing a Strep-tag
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- C07K 2319/35: containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are specific CD27 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD27L-associated disease or disorder. The CD27 receptor agonist proteins provided herein comprise three soluble CD27L domains an and Fc fragment. The CD27 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

## Claims

### Claim 1

A nucleic acid molecule encoding a cluster of differentiation 27 (CD27) receptor agonist protein, whereby said protein is a single-chain fusion polypeptide comprising:
(i) a first soluble CD27L (CD27 ligand) domain,
(ii) a first peptide linker having 3 to 8 amino acids,
(iii) a second soluble CD27L domain,
(iv) a second peptide linker having 3 to 8 amino acids,
(v) a third soluble CD27L domain,
(vi) a hinge-linker selected from the group consisting of SEQ ID NOs: 16 and 19-24, and
(vii) an antibody Fc fragment consisting of the amino acid sequence of SEQ ID NO: 13 or amino acids 1-217 of SEQ ID NO: 13;
wherein each of the soluble CD27L domains (i), (iii), and (v) comprises amino acids Asp56-Pro193 of SEQ ID NO: 1.

### Claim 2 (depends on 1)

The nucleic acid molecule of claim 1, wherein each of the soluble CD27L domains (i), (iii), and (v) consists of amino acids Glu51-Pro193 or Asp56-Pro193 of SEQ ID NO: 1.

### Claim 3 (depends on 1)

The nucleic acid molecule of claim 1, wherein each of the soluble CD27L domains (i), (iii), and (v) consists of amino acids Glu51-Pro193 or Asp56-Pro193 of SEQ ID NO: 1, with one or more of the soluble CD27L domains (i), (iii), and (v) having a mutation at the amino acid position Glu51, Trp55, Asn63, Arg83, Arg122, Arg138, Arg144, His123, His124, His148, Asn170, Arg179, or Asp182 of SEQ ID NO: 1.

### Claim 4 (depends on 1)

The nucleic acid molecule of claim 1, in operative linkage with an expression control sequence.

### Claim 5 (depends on 4)

An expression vector comprising the nucleic acid molecule of claim 4.

### Claim 6 (depends on 4)

A cell or a non-human organism transformed or transfected with the nucleic acid molecule of claim 4.

### Claim 7 (depends on 1)

The nucleic acid molecule of claim 1, comprising SEQ ID NO: 37.

### Claim 8 (depends on 1)

The nucleic acid molecule of claim 1, comprising nucleotides 35 to 2146 of SEQ ID NO: 37.

### Claim 9 (depends on 1)

The nucleic acid molecule of claim 1, comprising nucleotides 95 to 2146 of SEQ ID NO: 37.

### Claim 10 (depends on 8)

An expression vector comprising the nucleic acid molecule of claim 8, in operative linkage with an expression control sequence.

### Claim 11 (depends on 9)

An expression vector comprising the nucleic acid molecule of claim 9, in operative linkage with an expression control sequence.

### Claim 12 (depends on 8)

A cell comprising the nucleic acid molecule of claim 8.

### Claim 13 (depends on 9)

A cell comprising the nucleic acid molecule of claim 9.

### Claim 14 (depends on 12)

The cell according to claim 12, which is a eukaryotic cell.

### Claim 15 (depends on 14)

The cell according to claim 14, wherein the cell is a mammalian cell.

### Claim 16 (depends on 15)

The cell according to claim 15, wherein the cell is a Chinese Hamster Ovary (CHO) cell.

### Claim 17 (depends on 13)

The cell according to claim 13, which is a eukaryotic cell.

### Claim 18 (depends on 17)

The cell according to claim 17, wherein the cell is a mammalian cell.

### Claim 19 (depends on 18)

The cell according to claim 18, wherein the cell is a Chinese Hamster Ovary (CHO) cell.
